2024/09/20 17:37:47 | |
---|---|
Price | |
9.834 EUR | |
Difference | -2.39% (-0.24) |
ISIN | ES0171996087 |
Symbol | GRF |
Exchange | BME Continuous Market |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 6,237 EUR |
Benchmark | IBEX 35 |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 10.10 EUR |
High | 10.24 EUR |
Low | 9.834 EUR |
Close (prev. day) | 10.075 EUR |
VWAP | 9.927669 EUR |
Volume (pcs) | 2,051,038 |
Trading volume | 20,362,027.12 |
Number of trades | 3,060 |
Last size | 15 |
Related Futures | 33 |
Related Options | - |
Date | Headline | Download | |
2024/09/11 | Global Equity Ratings | ||
2024/09/05 | Global Equity Ratings | ||
2024/08/12 | Global Equity Ratings | ||
2024/07/24 | Global Equity Ratings | ||
2024/07/12 | Global Equity Ratings |
2024/09/20 17:37:47 | |
---|---|
Price | |
9.834 EUR | |
Difference | -2.39% (-0.24) |
ISIN | ES0171996087 |
Symbol | GRF |
Exchange | BME Continuous Market |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 6,237 EUR |
Benchmark | IBEX 35 |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 10.10 EUR |
High | 10.24 EUR |
Low | 9.834 EUR |
Close (prev. day) | 10.075 EUR |
VWAP | 9.927669 EUR |
Volume (pcs) | 2,051,038 |
Trading volume | 20,362,027.12 |
Number of trades | 3,060 |
Last size | 15 |
6m | 1Y | 3Y | |
Perf (%) | +22.01% | -24.53% | -55.70% |
Perf (abs.) | +1.77 | -3.20 | -12.37 |
Beta | 1.32 | 1.99 | 1.18 |
Volatility | 47.75 | 79.63 | 58.01 |
Ø price 5 days | Ø volume 5 days (pcs.) | 10.067 EUR (1,282,323) |
Ø price 30 days | Ø volume 30 days (pcs.) | 9.484 EUR (1,709,974) |
Ø price 100 days | Ø volume 100 days (pcs.) | 9.288 EUR (2,347,698) |
Ø price 250 days | Ø volume 250 days (pcs.) | 10.163 EUR (2,850,141) |
YTD High | date | 15.630 EUR (2024/01/02) |
YTD Low | date | 6.362 EUR (2024/03/06) |
52 Weeks High | date | 15.920 EUR (2023/12/29) |
52 Weeks Low | date | 6.362 EUR (2024/03/06) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
BME Continuous Market | 2024/09/20 | 17:37 | 9.834 EUR | 20.36 | 3,060 |
Berlin | 2024/09/20 | 17:55 | 9.81 EUR | 0.00 | 13 |
Duesseldorf | 2024/09/20 | 16:31 | 9.98 EUR | 0.00 | 4 |
FINRA other OTC Issues | 2024/09/11 | 19:14 | 10.41 USD | 0.01 | 1 |
Frankfurt | 2024/09/20 | 08:25 | 10.00 EUR | 0.00 | 1 |
Hanover | 2024/09/20 | 17:25 | 9.892 EUR | 0.00 | 2 |
London Stock Exchange European Trade Reporting | 2024/09/20 | 17:30 | 9.919 EUR | 0.38 | 2 |
Munich | 2024/09/20 | 08:18 | 10.06 EUR | 0.00 | 1 |
Stuttgart | 2024/09/20 | 08:12 | 9.904 EUR | 0.00 | 1 |
Tradegate | 2024/09/20 | 17:59 | 9.742 EUR | 0.02 | 13 |
Vienna Stock Exchange | 2024/09/20 | 15:30 | 10.035 EUR | 0.00 | 4 |
GRIFOLS SA |
- - |
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan - 08174 Barcelona |
Telefon: +34-93-571-02-21 |
Fax: +34-93-571-02-67 |
E-mail: - |
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain. |
Nacho Abia | Chairman of Managing Board |
Raimon Grifols Roura | Member of Executive Committee |
Thomas Glanzmann | Member of Executive Committee |
Víctor Grífols Deu | Member of Executive Committee |
Thomas Heinrich Glanzmann | Chairman of Supervisory Board |
Enriqueta Felip Font | Member of Supervisory Board |
Albert Coma-Cros | Member of Supervisory Board |
Anne-Catherine Berner | Member of Supervisory Board |
James Costos | Member of Supervisory Board |
Montserrat Muñoz Abellana | Member of Supervisory Board |
Susana González Rodríguez | Member of Supervisory Board |
Tomás Dagá Gelabert | Member of Supervisory Board |
Íñigo Sánchez-Asiaín Mardones | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer